lyophilization comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | RP-HPLC, 214 nm | Wavelength affects relative peak areas |
| Identity confirmation | LC-MS/MS | Precursor and fragment ion masses compared |
| Common degradation | Deamidation, oxidation | Amide and methionine residues are main sites |
| Working solution storage | 2-8 °C, short term | Longer holding favours frozen aliquots |
| Adsorption risk | Higher below 1 mg/mL | Glass and plastic surfaces both affected |
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
==== Pancreatic cancer ==== First-in-human application of different αvβ6-integrin radiotracers has demonstrated that 68Ga-Trivehexin performed especially well in detecting pancreatic cancer, showing high uptake in tumor lesions and low background in the gastrointestinal tract (GI tract) (see image). Since its introduction, 68Ga-Trivehexin has been used predominantly for PET/CT imaging of pancreatic ductal adenocarcinoma (PDAC), for example, in single cases and two cohorts (12 and 44 patients, respectively) of suspected or known PDAC.
== Analysis == Quincy Institute's political scientist Annelle Sheline has argued that Trump's plan for Gaza would not only constitute ethnic cleansing, but would also destabilize the Middle East, since the displacement of Palestinians into Jordan would provoke a period of social upheaval that could topple the Jordanian monarchy and create an entirely new state in the region. She argued that if such an event were to take place, the Jordanian Muslim Brotherhood could seize control of the country. This view has been supported by Paul Piller (fellow at the Quincy Institute) who argued that the displacement of Palestinians into Jordan would effectively end the Jordanian-Israeli peace agreement of 1994 and risk the overthrow of the Jordanian monarchy. Oraib Rantawi, head of the Amman Al Quds Center for Political Studies, said the plan would affect Jordan's demography, identity, and security. Egyptian officials warned that the inflow of hundreds of thousands of Hamas militants into the Sinai border resulting from the plan would destabilize the region and put Egypt's peace agreement with Israel in jeopardy. Also at the Quincy Institute, Rabwan Ahari has argued that Trump's proposal signals a clear and substantial departure from America having "even the pretense of supporting a two-state solution." They further argued that this plan amounted to a statement that Palestinian displacement was the goal of US policy surrounding the region.
=== Laboratory routes === For a few limited purposes when it is needed, pure iron is produced in the laboratory in small quantities by reducing the pure oxide or hydroxide with hydrogen, or forming iron pentacarbonyl and heating it to 250 °C so that it decomposes to form pure iron powder. Another method is electrolysis of ferrous chloride onto an iron cathode.
=== Gastrointestinal bleeding === The ratio is useful for the diagnosis of bleeding from the gastrointestinal (GI) tract in patients who do not present with overt vomiting of blood. In children, a BUN:Cr ratio of 30 or greater has a sensitivity of 68.8% and a specificity of 98% for upper gastrointestinal bleeding. A common assumption is that the ratio is elevated because of amino acid digestion, since blood (excluding water) consists largely of the protein hemoglobin and is broken down by digestive enzymes of the upper GI tract into amino acids, which are then reabsorbed in the GI tract and broken down into urea. However, elevated BUN:Cr ratios are not observed when other high protein loads (e.g., steak) are consumed. Renal hypoperfusion secondary to the blood lost from the GI bleed has been postulated to explain the elevated BUN:Cr ratio. However, other research has found that renal hypoperfusion cannot fully explain the elevation.
Sources: en.wikipedia.org
=== Non-dairy milk offerings === In 1997, Starbucks first offered non-dairy milk at its U.S. stores with the introduction of soy milk. In 2007, Starbucks stopped using milk originating from rBGH-treated cows. The company also adopted a new dairy standard for all espresso-based drinks, switching from whole to 2% reduced fat milk. In 2015, Starbucks began serving coconut milk. In 2016, it began serving almond milk. In January 2020, oat milk became available nationally. The company also offers non-dairy creamers at retail in partnership with Nestlé SA. CEO Kevin Johnson said in a 2020 interview that, milk substitutes would be a big part of reducing carbon emissions. That effort has prompted vegans, environmentalists, people with lactose intolerance and others to urge the company to eliminate the upcharge for drinks made with dairy-free milk. PETA encouraged sit-ins at Starbucks locations and purchased Starbucks stock to draw attention to what they believe is an unfair charge. A Starbucks Canada spokesperson told ET Canada that customizations such as added flavours, non-dairy beverages or an additional shot of espresso, would incur an additional charge. In December 2020, Starbucks announced it would offer Oatly oat milk in all US stores starting in spring 2021. With the launch of their holiday menu in November 2024, Starbucks ended the upcharge for non-dairy milk additions to drinks.
== History of ITC == The history of ITC can be traced back to the 1930s when isothermal calorimetry was used to study chemical reactions. In 1965 Christensen and Izatt introduced titration calorimetry as a method for simultaneously determining the equilibrium constant and enthalpy. The ITC technique was then developed by H. D. Johnston in 1968 as a part of his Ph.D. dissertation at Brigham Young University, and was considered niche until introduced commercially by MicroCal Inc. in 1988. In 1978, Beaudette and Langerman conducted one of the earliest calorimetric binding studies using a small volume isoperibol titration calorimeter and a decade later, in 1989, Wiseman, Williston, Brandts, and Lin demonstrated its application in biological systems, marking the beginning of titration calorimetry as a valuable tool for studying biological equilibria. Originally, ITC was most often used to study the binding of small molecules (such as medicinal compounds) to larger macromolecules (proteins, DNA etc.) in a label-free environment. Its application has now broadened, aided by modern improvements, making it possible to measure the heat effects as small as 0.1 μcal (0.4 μJ) and determine the binding constants (K) as high as 108–109 M−1.
== ANA subtypes == ANAs are found in many disorders, as well as some healthy individuals. These disorders include: systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjögren syndrome, scleroderma, polymyositis, dermatomyositis, primary biliary cirrhosis, drug induced lupus, autoimmune hepatitis, multiple sclerosis, discoid lupus, thyroid disease, antiphospholipid syndrome, juvenile idiopathic arthritis, psoriatic arthritis, juvenile dermatomyositis, idiopathic thrombocytopaenic purpura, infection and cancer. These antibodies can be subdivided according to their specificity, and each subset has different propensities for specific disorders.
Sources: en.wikipedia.org
Although ultimately discounting brain surgery as carrying too much risk, physicians and neurologists such as William Mayo, Thierry de Martel, Richard Brickner, and Leo Davidoff had, before 1935, entertained the proposition. Inspired by Julius Wagner-Jauregg's development of malarial therapy for the treatment of general paresis of the insane, the French physician Maurice Ducosté reported in 1932 that he had injected 5 ml of malarial blood directly into the frontal lobes of over 100 paretic patients through holes drilled into the skull. He claimed that the injected paretics showed signs of "uncontestable mental and physical amelioration" and that the results for psychotic patients undergoing the procedure were also "encouraging". The experimental injection of fever-inducing malarial blood into the frontal lobes was also replicated during the 1930s in the work of Ettore Mariotti and M. Sciutti in Italy and Ferdière Coulloudon in France. In Switzerland, almost simultaneously with the commencement of Moniz's leucotomy programme, the neurosurgeon François Ody had removed the entire right frontal lobe of a catatonic schizophrenic patient. In Romania, Ody's procedure was adopted by Dimitri Bagdasar and Constantinesco working out of the Central Hospital in Bucharest. Ody, who delayed publishing his own results for several years, later rebuked Moniz for claiming to have cured patients through leucotomy without waiting to determine if there had been a "lasting remission".
Colombia has more than 3,950 research groups in science and technology. iNNpulsa, a government body that promotes entrepreneurship and innovation in the country, provides grants to startups, in addition to other services it and institutions provide. Colombia was ranked 71st in the Global Innovation Index in 2025. Co-working spaces have arisen to serve as communities for startups large and small. Organizations such as the Corporation for Biological Research (CIB) for the support of young people interested in scientific work has been successfully developed in Colombia. The International Center for Tropical Agriculture based in Colombia investigates the increasing challenge of global warming and food security. Important inventions related to medicine have been made in Colombia, such as the first external artificial pacemaker with internal electrodes, invented by the electrical engineer Jorge Reynolds Pombo, an invention of great importance for those who suffer from heart failure. Also invented in Colombia were the microkeratome and keratomileusis technique, which form the fundamental basis of what now is known as LASIK (one of the most important techniques for the correction of refractive errors of vision) and the Hakim valve for the treatment of hydrocephalus. Colombia has begun to innovate in military technology for its army and other armies of the world; especially in the design and creation of personal ballistic protection products, military hardware, military robots, bombs, simulators and radar. Some leading Colombian scientists are Joseph M.
Cystathionine gamma lyase also shows gamma-synthase activity depending on the concentrations of reactants present. The mechanisms are the same until they diverge after formation of the vinyl glyoxylate derivative. In the gamma synthase mechanism, the gamma carbon is attacked by a sulfur nucleophile, resulting in the formation of a new sulfur-gamma carbon bond.
Crucibles used to contain plutonium need to be able to withstand its strongly reducing properties. Refractory metals such as tantalum and tungsten along with the more stable oxides, borides, carbides, nitrides and silicides can tolerate this. Melting in an electric arc furnace can be used to produce small ingots of the metal without the need for a crucible. Cerium is used as a chemical simulant of plutonium for development of containment, extraction, and other technologies.
Sources: en.wikipedia.org
Filtering removes particulate matter that can block columns or scatter light. A 0.22 micrometre membrane is typical, and the filter material should be checked for peptide adsorption.
Peptides can bind to glass and plastic, so a fraction of the material leaves the solution. The effect is proportionally larger in dilute samples and can bias quantitative results.
Reverse-phase high-performance liquid chromatography is the most widely reported approach. Purity figures should always be quoted together with the wavelength, gradient, and integration parameters used.
Long-term storage is usually at minus 20 to minus 80 degrees Celsius in a sealed, desiccated container. Working aliquots can be held briefly at 2 to 8 degrees Celsius.